https://european-biotechnology.net/wp-content/uploads/2025/07/RheticusEvonik-e1752130242507-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-10 11:44:112025-07-10 11:44:11First step towards scaling chemical production from CO₂
https://european-biotechnology.net/wp-content/uploads/2025/07/Exosome-Schmuckbild-e1752043172924.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-09 06:41:522025-07-09 06:41:52Ciloa SAS secures €6.5m to advance lead candidate APN-sEV into clinical development
https://european-biotechnology.net/wp-content/uploads/2025/07/Solarfoods2-e1751963179861-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-08 08:29:152025-07-08 08:29:15Solar Foods continues expansion in the US
https://european-biotechnology.net/wp-content/uploads/2025/07/EC-Life-Sciences-Strategy-e1751894302405.jpg360639Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-07 13:41:172025-07-07 13:41:17European Commission to fund Life Sciences Strategy using Cohesion Fund resources
https://european-biotechnology.net/wp-content/uploads/2025/07/Vetter-e1751364099507.jpg304540Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-07-01 13:39:202025-07-01 13:39:20Vetter invests US$285m in Chicago production facility
